Background/Purpose: This study investigated the correlation between antibiotic consumption and the incidence of health care-associated infections (HCAIs) caused by imipenem-resistant Acinetobacter baumannii (IRAB) at a hospital in Taiwan from 2005 to 2010. Methods: Data on annual consumption (defined daily dose per 1000 patient-days) of extendedspectrum cephalosporins, b-lactam-b-lactamase inhibitor combinations, carbapenems, aminoglycosides, and fluoroquinolones from 2005 to 2010 were analyzed. Yearly aggregated data on the number of nonduplicate clinical IRAB isolates causing HCAI were collected. The incidence rates of HCAI caused by IRAB were defined as the number of patients infected with IRAB per 1000 inpatient-days. Results: The trend of total consumption (defined daily dose per 1000 patient-days) of extended-spectrum cephalosporins, carbapenems, and fluoroquinolones was significantly increased, but the use of aminoglycosides decreased during 2005 to 2010. During the same period, the incidence of HCAI caused by IRAB gradually increased. The consumptions of carbapenems and fluoroquinolones were positively correlated with the incidence of HCAI caused by IRAB. There was no significant association between the use of extended-spectrum cephalosporins, b-lactam-b-lactamase inhibitor combinations, and aminoglycosides and the incidence of HCAI caused by IRAB.
Introduction
The incidence of health care-associated infection (HCAI) caused by Gram-negative bacteria, particularly multidrugresistant bacteria, has gradually increased and exerted a global impact on public health.
1e8 Moreover, infections caused by resistant microorganisms would lead to many adverse outcomes, including extended length of stay, higher health care costs, and greater hospital morbidity and mortality. 3, 5 Acinetobacter baumannii has recently emerged as a major pathogen causing HCAI and is notorious for its capacity to rapidly accumulate mechanisms of antibiotics resistance. 9 Multidrug-resistant A. baumannii can cause various types of HCAI, including bacteremia, pneumonia, meningitis, urinary tract infection, and wound infections. 9, 10 Prior use of broad-spectrum antibiotics was demonstrated to be a major risk factor for acquiring multidrug-resistant A. baumannii infections. 10, 11 Although several studies have investigated the relationship between antibiotic consumption and antibiotic resistance, the inconsistent results among these studies may be attributable to differences in resistance profiles and antibiotic prescribing practices in different countries.
12e18 These findings support the necessity of monitoring aggregate antibacterial drug use at local and national levels in order to evaluate the associations between the use of antibiotics and emerging antibiotic resistances. This study investigated the correlations between antibiotic consumption and incidence of HCAI caused by IRAB from 2005 to 2010 at a hospital in southern Taiwan.
Materials and methods

Setting
Chi Mei Medical Center, Liouying branch, is an 800-bed hospital that started to provide primary and tertiary care in southern Taiwan in 2005. The number of annual patientdays at the hospital significantly increased from 169,886 in 2005 to 256,563 in 2010 (p < 0.002). Yearly aggregated data on the number of nonduplicate clinical carbapenemresistant A. baumannii (CRAB) isolates causing HCAI were collected. HCAI was defined according to the National Nosocomial Infection Surveillance guidelines. 19 The incidence rates of HCAI caused by IRAB were defined as the number of patients with HCAI caused by IRAB per 1000 inpatient-days. In our hospital, all attending physicians are not allowed to prescribe antimicrobial agents, including at least second-generation cephalosporins, b-lactam-blactamase inhibitor combinations, carbapenems (imipenem, meropenem, and ertapenem), and fluoroquinolones, without the permission of the infection disease specialists. 
Antibiotic agents and consumption
Bacterial isolates
A. baumannii isolates were identified using conventional biochemical tests as well as two commercial identification kits, Api20NE (bioMerieux) and the Phoenix System (Becton Dickinson, Sparks, MD, USA). Disk diffusion methods were applied for antibiotic susceptibility tests. 
Statistical analysis
Linear regression analysis was used to analyze the trend in annual patient-days, annual consumption of antibiotic agents, and the trend in the imipenem resistant rate of A. baumannii causing all HCAI with time. Pearson's correlation coefficient was used to determine the relationship between annual antibiotic consumption and trends in incidence of HCAI caused by IRAB. A p value <0.05 was considered statistically significant.
Results
Annual antibiotic consumption
In general, the usage of each antibiotic agent varied with years ( Fig. 1 ). Fluoroquinolones were the most commonly used antibiotics, followed by extended-spectrum cephalosporins. A significant increase in consumption was found for extended-spectrum cephalosporins, carbapenems, and fluoroquinolones from 2005 to 2010. By contrast, the consumption of aminoglycosides was significantly decreased during the study period. Additionally, the use blactam-b-lactamase inhibitor combinations and sulbactam remains stable with time.
Trend of antibiotic resistance among A. baumannii isolates
A total of 473 nonduplicate A. baumannii isolates causing HCAIs were identified during the study period and tested for susceptibility. Fig. 2 shows the trends of imipenem resistance rate among A. baumannii isolates. The incidence of HCAI caused by IRAB (p Z 0.032) was found to be significantly increased with time. Additionally, we found that only about 30e40% of A. baumannii isolates were susceptible to amikacin, ceftazidime, and ciprofloxacin; however, the incidence of HCAI caused by amikacin-, ceftazidime-, or ciprofloxacin-resistant A. baumannii remained stable during the study period.
Correlation between antibiotics consumption and the incidence of HCAI caused by IRAB
The relationships between the incidence of HCAI caused by IRAB and the annual consumption of various antibiotics are shown in Table 1 . A positive correlation between the increase in the use of fluoroquinolones and carbapenems, and the incidence of HCAI caused by IRAB was noted. By contrast, we did not find any significant relationship between the use of extended-spectrum cephalosporins, b-lactam-b-lactamase inhibitor combinations, sulbactam, and aminoglycosides, and the incidence of HCAI caused by IRAB. However, there was no significant correlation between the consumption of each fluoroquinolone (including ciprofloxacin, levofloxacin, and moxifloxacin) and carbapenem (including ertapenem, meropenem, and imipenem) and the incidence of HCAI caused by IRAB.
Discussion
This study evaluated the association between antibiotic consumption and the incidence of HCAI caused by IRAB in a hospital in southern Taiwan during a 6-year period. Overall, the trend in consumption of most antibiotics, including extended-spectrum cephalosporins, carbapenems, and fluoroquinolones, was significantly increased during the study period. For carbapenems, in particular, and fluoroquinolones, the use of each antibiotic dramatically increased by about 3.5-fold and 2-fold, respectively. On the contrary, the consumption of aminoglycosides significantly decreased during this period, which might be attributable to the notable nephrotoxicity of these agents.
In this institution, HCAI caused by IRAB significantly increased during the study period. By contrast, the incidence of HCAI caused by amikacin-, ceftazidime-, and ciprofloxacin-resistant A. baumannii remained stable. In the past year of this study, more than half of A. baumannii isolates were resistant to imipenem, and only less than 40% of A. baumannii isolates remained susceptible to amikacin, ceftazidime, and ciprofloxacin. Our findings are consistent with those of a previous study conducted in a medical center in northern Taiwan, 18 which showed the high resistance rate of A. baumannii isolates causing HCAI. All of the above findings would suggest that the choices of antibiotics are limited in this era of A. baumannii with in vitro high antibiotic resistance. Novel antibiotics or combination therapies should be considered when dealing with this antibiotic-resistant pathogendA. baumannii.
In this study, we found that the increasing use of carbapenems was associated with the increasing incidence of HCAIs caused by IRAB. This is consistent with the finding of Lai et al 18 and Hsu et al 23 that there is a positive correlation between the use of carbapenems and imipenem-resistant Acinetobacter spp. However, while looking for the specific association between ertapenem, imipenem, meropenem, and the incidence of HCAI caused by IRAB, we did not find any significant correlation. Although we demonstrated the increasing use of total carbapenems and the incidence of HCAI caused by IRAB in this study, further study is necessary to determine the association between each carbapenem and the incidence of HCAI caused by IRAB. Nevertheless, our findings suggest that in the hospital where imipenem resistance is endemic for A. baumannii isolates and the prescription rate of broad-spectrum antibiotic agents is high, caution in antibiotic use would play an important role in managing high resistance rates.
In addition to carbapenems, we also found that the use of fluoroquinolones was positively associated with the incidence of HCAI caused by IRAB. In concordance with carbapenems, the incidence of HCAI caused by IRAB correlated only with the total consumption of fluoroquinolones, but not with any of the fluoroquinolones, such as ciprofloxacin, levofloxacin, and moxifloxacin. This is contrary to the studies carried out for Pseudomonas aeruginosa, which showed that the associations between the antibiotic resistance rate of bacteria and ciprofloxacin, levofloxacin, or ciprofloxacin plus levofloxacin varied. 23e25 The difference may be attributable to the different pathogens or study design used, so we still need more data to confirm the specific role of each fluoroquinolone. Currently, based on our findings, it may be suggested that cautious use of fluoroquinolones is helpful in reducing HCAIs caused by IRAB.
This study has several limitations. Although we found a significant correlation between antibiotic use and the incidence of HCAI caused by IRAB, the etiology behind the emergence of drug-resistant bacteria in our hospital is complicated, and selective pressure from the widespread use of antibiotic agents might be only one of the causes. The incidence of IRAB could have been affected by multiple factors, such as infection control measures and hand hygiene, or operational changes in the hospital. In addition, because this investigation is basically an epidemiological surveillance study only, we did not analyze the impact of the duration of exposure to antibiotics, or the clonal spread of resistant bacteria on the trend of the incidence of HCAI caused by IRAB. Finally, we did not use molecular methods for identification of the A. baumannii complex, which included at least three Acinetobacter genomic species: A. baumannii, Acinetobacter pittii, and Acinetobacter nosocomialis. Therefore, some misidentifications of bacterial species can occur and further affect our analysis.
In conclusion, we found that the consumption of most of the antibiotics, except aminoglycosides, was significantly increased during this 6-year study in a Taiwanese hospital. The increasing use of carbapenems and fluoroquinolones was associated with the increasing incidence of HCAI caused by IRAB.
